Total Payments
$76,336
2024 Payments
$149.71
Companies
10
Transactions
61
Medicare Patients
348
Medicare Billing
$102,797
Payment Breakdown by Category
Other$40,002 (52.4%)
Travel$14,533 (19.0%)
Consulting$12,058 (15.8%)
Research$8,828 (11.6%)
Food & Beverage$855.63 (1.1%)
Education$59.78 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $36,932 | 2 | 48.4% |
| Travel and Lodging | $14,533 | 3 | 19.0% |
| Consulting Fee | $12,058 | 10 | 15.8% |
| Unspecified | $8,828 | 30 | 11.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,070 | 2 | 4.0% |
| Food and Beverage | $855.63 | 12 | 1.1% |
| Education | $59.78 | 2 | 0.1% |
Payments by Type
General
$67,508
31 transactions
Research
$8,828
30 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $36,959 | 3 | $0 (2023) |
| Astellas Pharma Inc | $15,433 | 9 | $0 (2023) |
| Astellas Pharma Global Development | $8,828 | 30 | $0 (2022) |
| ABBVIE INC. | $6,127 | 8 | $0 (2024) |
| Genentech USA, Inc. | $5,225 | 3 | $0 (2022) |
| Amgen Inc. | $2,400 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $1,234 | 4 | $0 (2023) |
| Incyte Corporation | $47.81 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $41.50 | 1 | $0 (2022) |
| PFIZER INC. | $39.99 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $149.71 | 1 | ABBVIE INC. ($149.71) |
| 2023 | $22,305 | 8 | Genentech, Inc. ($18,182) |
| 2022 | $37,754 | 18 | Genentech, Inc. ($18,778) |
| 2021 | $6,693 | 10 | Genentech USA, Inc. ($3,575) |
| 2020 | $4,327 | 11 | Astellas Pharma Global Development ($4,327) |
| 2019 | $5,060 | 12 | Astellas Pharma Global Development ($2,540) |
| 2017 | $47.81 | 1 | Incyte Corporation ($47.81) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $149.71 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $130.54 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2023 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $39.99 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2023 | Genentech, Inc. | — | Grant | Cash or cash equivalent | $18,181.82 | General |
| 04/11/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2023 | Astellas Pharma Inc | Xospata (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $670.00 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Astellas Pharma US Inc | Xospata (Drug) | Education | In-kind items and services | $19.79 | General |
| Category: Oncology | ||||||
| 01/23/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2022 | Genentech, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: BioOncology | ||||||
| 12/10/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $109.22 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2022 | Astellas Pharma Inc | Xospata (Drug) | Travel and Lodging | Cash or cash equivalent | $80.30 | General |
| Category: Oncology | ||||||
| 10/16/2022 | Astellas Pharma Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $193.44 | General |
| Category: Oncology | ||||||
| 10/16/2022 | Astellas Pharma Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: Oncology | ||||||
| 10/16/2022 | Astellas Pharma Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $10.16 | General |
| Category: Oncology | ||||||
| 10/16/2022 | Astellas Pharma Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $2.41 | General |
| Category: Oncology | ||||||
| 10/14/2022 | Astellas Pharma Inc | Xospata (Drug) | Travel and Lodging | Cash or cash equivalent | $13,818.18 | General |
| Category: Oncology | ||||||
| 10/14/2022 | Astellas Pharma Inc | Xospata (Drug) | Travel and Lodging | Cash or cash equivalent | $634.37 | General |
| Category: Oncology | ||||||
| 10/14/2022 | Astellas Pharma Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: Oncology | ||||||
| 09/18/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $41.50 | General |
| 06/30/2022 | Genentech, Inc. | — | Grant | Cash or cash equivalent | $18,750.00 | General |
| 06/23/2022 | Astellas Pharma US Inc | Xospata (Drug) | Consulting Fee | Cash or cash equivalent | $365.00 | General |
| Category: Oncology | ||||||
| 06/17/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2022 | Astellas Pharma Global Development | Xospata (Drug) | — | In-kind items and services | $87.00 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. • Category: Oncology | ||||||
| 02/24/2022 | Genentech USA, Inc. | VENCLEXTA (Biological) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Astellas Pharma Global Development | $4,121 | 10 |
| A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $1,768 | 7 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $1,519 | 3 |
| A Phase 12 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Astellas Pharma Global Development | $753.62 | 2 |
| A PHASE 1/2 OPEN-LABEL, DOSE ESCALATION STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ASP2215 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. | Astellas Pharma Global Development | $205.61 | 1 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $192.70 | 2 |
| A Phase 1 Parallel Design Study to Assess the Effect of Itraconazole, Fluconazole and Rifampin on the Single-dose Pharmacokinetics of ASP2215 in Healthy Subjects | Astellas Pharma Global Development | $53.62 | 1 |
| A Phase 1 Study to Investigate the Effect of Food on the Pharmacokinetics of ASP2215 in Healthy Adult Subjects | Astellas Pharma Global Development | $53.62 | 1 |
| A Phase 1 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2220 | Astellas Pharma Global Development | $53.62 | 1 |
| A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of 14C-ASP2215 in Patients with Advanced Solid Tumors | Astellas Pharma Global Development | $53.62 | 1 |
| A Phase 1, Single-dose, Open-label, Randomized Parallel Study to Assess the Relative Bioavailability Between 2 ASP2215 Tablet Formulations in Healthy Adult Subjects | Astellas Pharma Global Development | $53.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 95 | 241 | $203,280 | $28,268 |
| 2022 | 3 | 87 | 269 | $196,356 | $29,602 |
| 2021 | 3 | 89 | 283 | $211,226 | $33,341 |
| 2020 | 2 | 77 | 156 | $106,280 | $11,586 |
Total Patients
348
Total Services
949
Medicare Billing
$102,797
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 65 | 210 | $162,330 | $24,919 | 15.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $15,190 | $2,261 | 14.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 16 | 17 | $25,760 | $1,088 | 4.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 64 | 232 | $179,336 | $27,164 | 15.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $13,020 | $1,809 | 13.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 11 | 25 | $4,000 | $628.10 | 15.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 61 | 219 | $169,287 | $26,469 | 15.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 51 | $27,834 | $4,709 | 16.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $14,105 | $2,162 | 15.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 40 | 83 | $64,159 | $6,765 | 10.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 37 | 73 | $42,121 | $4,821 | 11.4% |
About Dr. Catherine Smith, M.D
Dr. Catherine Smith, M.D is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164471488.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Catherine Smith, M.D has received a total of $76,336 in payments from pharmaceutical and medical device companies, with $149.71 received in 2024. These payments were reported across 61 transactions from 10 companies. The most common payment nature is "Grant" ($36,932).
As a Medicare-enrolled provider, Smith has provided services to 348 Medicare beneficiaries, totaling 949 services with total Medicare billing of $102,797. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location San Francisco, CA
- Active Since 05/06/2006
- Last Updated 01/25/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1164471488
Products in Payments
- Xospata (Drug) $16,740
- XOSPATA (Drug) $8,755
- VENCLEXTA (Drug) $6,127
- VENCLEXTA (Biological) $5,253
- JAKAFI (Drug) $47.81
- XTANDI (Drug) $39.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736